Tandem Diabetes Care Inc (NASDAQ:TNDM) Director Edward L. Cahill sold 1,417 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $63.03, for a total value of $89,313.51. Following the sale, the director now owns 5,399 shares of the company’s stock, valued at approximately $340,298.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
TNDM stock traded down $0.12 during midday trading on Thursday, hitting $59.65. The company’s stock had a trading volume of 11,715 shares, compared to its average volume of 1,447,714. The company’s 50-day moving average is $63.72. The company has a current ratio of 2.53, a quick ratio of 2.21 and a debt-to-equity ratio of 0.11. Tandem Diabetes Care Inc has a 1 year low of $26.40 and a 1 year high of $74.81. The stock has a market cap of $3.51 billion, a PE ratio of -23.36 and a beta of 0.33.
Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Thursday, August 1st. The medical device company reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.20. Tandem Diabetes Care had a negative return on equity of 19.31% and a negative net margin of 19.55%. The business had revenue of $93.26 million for the quarter, compared to analysts’ expectations of $69.95 million. During the same quarter in the previous year, the firm earned ($0.33) earnings per share. The business’s revenue was up 173.2% on a year-over-year basis. Research analysts expect that Tandem Diabetes Care Inc will post -0.65 earnings per share for the current year.
TNDM has been the topic of several analyst reports. BidaskClub raised Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 23rd. Craig Hallum reaffirmed a “buy” rating and set a $84.00 target price (up previously from $70.00) on shares of Tandem Diabetes Care in a research report on Wednesday, May 1st. Stifel Nicolaus lifted their target price on Tandem Diabetes Care from $58.00 to $70.00 and gave the company a “hold” rating in a research report on Wednesday, May 1st. Oppenheimer lifted their target price on Tandem Diabetes Care from $80.00 to $84.00 in a research report on Friday, August 2nd. Finally, Bank of America reaffirmed a “neutral” rating and set a $65.00 target price on shares of Tandem Diabetes Care in a research report on Friday, May 17th. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $68.38.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Featured Article: Book Value Per Share – BVPS
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.